AOD-9604

What Is AOD 9604 Peptide?

AOD 9604 is a short synthetic peptide derived from the C-terminal region of human growth hormone, containing amino acids 176–191. The name AOD originally referred to “Anti-Obesity Drug,” while 9604 was the compound’s internal development code during early research.

Unlike full human growth hormone, AOD 9604 does not appear to elevate IGF-1, activate the full GH receptor pathway, or produce broader anabolic effects. This distinction is relevant for researchers evaluating the peptide specifically in the context of fat metabolism and body composition.

AOD 9604 has been cited in some sources as having GRAS status for use as a food ingredient. This does not constitute FDA approval as a therapeutic drug, and it does not authorize injectable, clinical, or therapeutic applications.

Structure and Classification

AOD 9604 is a 16-amino-acid peptide fragment classified as a research compound in the United States and is not FDA-approved as a therapeutic medication. Its primary research interest stems from its selective involvement in fat metabolism pathways, particularly lipolysis and lipogenesis. Because it does not act like a traditional growth hormone secretagogue, it is generally placed in a distinct category from peptides such as Sermorelin, Tesamorelin, or CJC-1295.

AOD Peptide Mechanism of Action

AOD 9604 has been studied for its potential activity in adipose tissue, with its proposed mechanism centered on lipolysis, the process by which stored triglycerides are broken down into free fatty acids. Research discussions describe AOD 9604 as potentially acting through beta-3 adrenergic receptor pathways in fat cells, which may influence hormone-sensitive lipase and fat breakdown. It has also been studied for its potential to inhibit lipogenesis, the formation of new fat cells.

AOD 9604 does not appear to stimulate IGF-1 production or disrupt glucose metabolism as full human growth hormone may, making it of interest in research settings where isolated fat metabolism is the focus rather than systemic GH-axis activation. These mechanisms should be understood as research-based and not as established clinical outcomes.

Effects on HGH Levels

AOD 9604 is not a growth hormone secretagogue. It does not stimulate the pituitary gland, increase circulating growth hormone levels, or elevate IGF-1. This distinguishes it from peptides such as Sermorelin and CJC-1295, which act on the hypothalamic-pituitary axis to stimulate endogenous GH release. Researchers and practitioners comparing peptide classes should note that AOD 9604 and GH secretagogues represent different mechanistic categories that should not be treated as interchangeable in protocol discussions.

AOD 9604 Peptide Benefits

Research on AOD 9604 covers fat metabolism, metabolic safety, and early musculoskeletal investigations. The evidence base varies significantly by study type and outcome, and preclinical findings are more consistent than human efficacy data overall.

• Fat Metabolism Research: Preclinical studies have shown activity consistent with lipolysis and inhibition of lipogenesis. Early-phase human studies explored these effects in overweight adults, but later human data have been mixed, and AOD 9604 has not been established as a reliably effective fat-loss agent in humans. Findings from early studies should not be interpreted as confirmation of clinical weight-loss efficacy.
• Metabolic Safety Profile: Phase 2 data showed no significant disruption of glucose metabolism and no elevation of IGF-1 across the studied dose ranges. This differentiates AOD 9604 from full-sequence human growth hormone, though these findings are specific to the doses and populations studied.
• Cartilage and Musculoskeletal Research: Some early in vitro and preclinical studies have explored AOD 9604 for cartilage repair. These findings remain preliminary, and further controlled human studies are needed before musculoskeletal applications can be discussed beyond investigational status.

Practitioners who are interested in these benefits should consider to buy AOD Peptide. Doctor Medica’s support staff can help guide practitioners on how to source from legitimate suppliers.

AOD 9604 Dose & Administration

All AOD 9604 dosing information should be treated with caution. No subcutaneous dosage has been validated through controlled human clinical trials, and injectable protocols discussed in practitioner settings are anecdotal rather than evidence-based.

• Subcutaneous Administration: Some practitioners have reported anecdotally subcutaneous doses of 250–500 mcg per day, often in fasted-state settings. These reports are not supported by controlled, injectable-trial data and should not be interpreted as validated dosing guidance.
• Published Human Trial Dosing: Published Phase 2b human trials used oral dosing of 1–5 mg per day. Because oral and injectable bioavailability differ significantly, oral trial dosing cannot be directly converted into subcutaneous protocols.
• Reconstitution and Storage: Lyophilized AOD 9604 is typically reconstituted with bacteriostatic water. Reconstituted solution should generally be stored at 2–8°C and protected from light. Practitioners should follow standard peptide handling procedures and product-specific documentation.
• Cycle Length: Cycle lengths of 8–16 weeks are sometimes referenced anecdotally, but these are not clinically validated and should be individualized based on research goals and professional judgment.

Legal Status of AOD 9604

Information current as of June 2026. Practitioners should verify the current regulatory status in their jurisdiction directly with the relevant authority before considering any AOD 9604-related protocol.

United States

AOD 9604 is not FDA-approved as a therapeutic drug. Its regulatory status under FDA compounding frameworks has evolved, and practitioners should consult current FDA guidance directly to confirm applicable restrictions before sourcing or discussing AOD 9604 in any clinical or research context.

Australia

Some secondary sources report AOD 9604 as Schedule 4 (prescription-only) under the Therapeutic Goods Administration framework. Practitioners should verify the current classification directly with the TGA before relying on this information, as scheduling status may change.

WADA

AOD 9604 is prohibited under WADA rules as a growth hormone fragment. Practitioners and researchers working with competitive athletes should treat AOD 9604 as a prohibited substance and verify the current prohibition status through official WADA materials before any discussion of protocols.

AOD 9604 Side Effects

Published tolerability data for AOD 9604 come primarily from oral clinical trial settings. Route-specific safety data for injectable use are more limited, and any discussion of side effects should reflect the level of evidence and the route of administration.

• Tolerability in Published Trials: In oral Phase 2b clinical trials, AOD 9604 was generally well tolerated, with no serious adverse events reported under those conditions. This finding applies to the oral route only and should not be generalized to injectable use.
• Injection Site Reactions: Standard subcutaneous injection reactions may occur with injectable use, including localized redness, mild swelling, or temporary discomfort. Appropriate aseptic technique and site rotation may help reduce these reactions.
• Long-Term Safety Data Gap: Long-term injectable safety data for AOD 9604 remain limited. This evidence gap should be communicated clearly in any research or protocol discussion involving injectable use.

AOD Peptide vs Tesamorelin, Sermorelin & CJC-1295

Tesamorelin is a GHRH analog that stimulates endogenous GH release, increasing IGF-1 and activating broader GH-axis effects. AOD 9604 does not stimulate the pituitary, elevate GH, or increase IGF-1. Tesamorelin also holds FDA approval for reducing excess abdominal fat in adults with HIV-associated lipodystrophy, an indication AOD 9604 does not have.

Meanwhile, Sermorelin stimulates the pituitary to release growth hormone and is commonly discussed in relation to GH deficiency and age-related endocrine changes. AOD 9604 is not a secretagogue and does not act through the hypothalamic-pituitary axis, placing it in a different mechanistic category for researchers focused on fat metabolism without GH-axis stimulation.

As for CJC-1295, it is a longer-acting GHRH analog designed to stimulate sustained GH and IGF-1 activity. AOD 9604 does not produce systemic elevations in GH or IGF-1, and its appeal in research settings lies in its more localized lipolytic mechanism. Practitioners evaluating AOD 9604 alongside secretagogue alternatives should confirm that verifiable purity documentation, LOT number traceability, and a certificate of analysis are available for each compound under consideration.

For practitioners considering to buy AOD Peptide, it is good to evaluate it in comparison with other peptides. Doctor Medica’s staff can provide more information on these comparisons, and can guide practitioners on how to source from qualified and legitimate sources.

Where Can Practitioners Buy AOD 9604 Online?

AOD 9604 is available for research purposes to qualified professionals only and is not intended for general consumer use. When evaluating suppliers, practitioners should prioritize those that can provide verifiable purity documentation, LOT number traceability, and a current certificate of analysis for each batch. Doctor Medica supports licensed professionals by offering sourcing guidance and access to relevant documentation. Practitioners looking to buy AOD 9604 wholesale from a verified research-grade supplier are encouraged to contact Doctor Medica’s staff directly for assistance.

FAQs

1. What is the AOD 9604 peptide?

AOD 9604 is a synthetic fragment of human growth hormone made up of amino acids 176–191, developed for research into fat metabolism and body composition. It is not FDA-approved as a therapeutic drug.

2. What does AOD 9604 do?

AOD 9604 is studied for its proposed role in lipolysis, the breakdown of stored fat, and lipogenesis, the formation of new fat cells. Unlike full human growth hormone, it does not appear to stimulate IGF-1 or activate systemic GH signaling.

3. Is AOD 9604 safe?

Within oral Phase 2b clinical trials, AOD 9604 was generally well tolerated, with no serious adverse events reported under those specific conditions. Long-term safety data for injectable use remain limited, and this evidence gap should be clearly discussed in any protocol context.

4. What is the AOD 9604 dose?

Subcutaneous dosing referenced in practitioner discussions is anecdotal and has not been validated by controlled human injectable trials. Published human trials used oral dosing; oral data should not be directly converted to injectable protocols.

5. Does AOD 9604 affect HGH levels?

AOD 9604 is not a growth hormone secretagogue and does not stimulate the pituitary gland. It does not appear to increase circulating GH or IGF-1, distinguishing it from peptides such as Sermorelin and CJC-1295.

References

1. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. doi:10.1159/000053183
2. Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab. 2013;3(1-2):7-15. doi:10.4021/jem157w
3. Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. doi:10.1210/endo.142.12.8522

For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.